肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

第17届国际骨髓瘤研讨会（IMW）：XPOVIO（Selinexor）的全新临床数据将被披露

2019-09-16 Allan MedSci原创

selinexor骨髓瘤Xpovio
关注

Karyopharm Therapeutics是一家专注于肿瘤学的制药公司，近日宣布，将在9月12日至15日举行的第17届国际骨髓瘤研讨会（IMW）上发表五篇重点介绍XPOVIO™（selinexor）临床数据的摘要。

Karyopharm Therapeutics是一家专注于肿瘤学的制药公司，近日宣布，将在9月12日至15日举行的第17届国际骨髓瘤研讨会（IMW）上发表五篇重点介绍XPOVIO™（selinexor）临床数据的摘要。

其中将介绍STORM研究，STORM研究中的骨髓瘤患者接受了selinexor联合地塞米松作为一线治疗手段，与MAMMOTH研究中selinexor联合地塞米松治疗难治性骨髓瘤患者（n=64）相比，死亡率的未调整危险比（HR）为0.64（p=0.043），而调整后的HR为0.55（p=0.009）。STORM研究中患者的中位OS为11.1个月，而MAMMOTH研究中患者的中位OS为9.2个月。


原始出处：

http://www.firstwordpharma.com/node/1666360#axzz5zU18ApSM

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685446, encodeId=ca281685446de, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sat Nov 30 13:22:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016737, encodeId=b6082016e37ec, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sun Feb 09 11:22:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994831, encodeId=26211994831fd, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Nov 17 19:22:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531273, encodeId=426c15312e30c, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16117, encryptionId=bb4d1611ea2, topicName=selinexor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6c12239440, createdName=zhixianchen, createdTime=Wed Sep 18 00:22:00 CST 2019, time=2019-09-18, status=1, ipAttribution=)]
    2019-11-30 chshh86

    #Xpovio#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1685446, encodeId=ca281685446de, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sat Nov 30 13:22:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016737, encodeId=b6082016e37ec, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sun Feb 09 11:22:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994831, encodeId=26211994831fd, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Nov 17 19:22:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531273, encodeId=426c15312e30c, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16117, encryptionId=bb4d1611ea2, topicName=selinexor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6c12239440, createdName=zhixianchen, createdTime=Wed Sep 18 00:22:00 CST 2019, time=2019-09-18, status=1, ipAttribution=)]
    2020-02-09 chenlianhui

    #临床数据#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1685446, encodeId=ca281685446de, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sat Nov 30 13:22:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016737, encodeId=b6082016e37ec, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sun Feb 09 11:22:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994831, encodeId=26211994831fd, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Nov 17 19:22:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531273, encodeId=426c15312e30c, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16117, encryptionId=bb4d1611ea2, topicName=selinexor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6c12239440, createdName=zhixianchen, createdTime=Wed Sep 18 00:22:00 CST 2019, time=2019-09-18, status=1, ipAttribution=)]
    2019-11-17 kcb069

    #研讨会#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1685446, encodeId=ca281685446de, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sat Nov 30 13:22:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016737, encodeId=b6082016e37ec, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sun Feb 09 11:22:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994831, encodeId=26211994831fd, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Nov 17 19:22:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531273, encodeId=426c15312e30c, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16117, encryptionId=bb4d1611ea2, topicName=selinexor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6c12239440, createdName=zhixianchen, createdTime=Wed Sep 18 00:22:00 CST 2019, time=2019-09-18, status=1, ipAttribution=)]
    2019-09-18 zhixianchen

    #selinexor#

    0

相关资讯

Blood:一期临床试验表明Selinexor对非霍奇金淋巴瘤具有良好的治疗效果

口服XPO1抑制selinexor在35 mg / m2的是一种安全的治疗方法，该药对R / R NHL患者而言具有令人鼓舞和持久的抗癌活性,

Blood：Selinexor联合低剂量硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤的疗效和安全性

中心点：Selinexor联合低剂量的硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤患者，安全且耐受性好。SVd疗法可获得较高的缓解率，PI非难治性患者ORR可达84%，而PI复发性患者的ORR也可达到43%。摘要：Selinexor是一种口服的核输出蛋白exportin1（XPO1）抑制剂。预临床研究表明，selinexor和蛋白酶体抑制剂(PI)可通过抑制NFκB信号和肿瘤抑制蛋白

NEJM：XPOVIO（Selinexor）治疗难治性多发性骨髓瘤的IIb期STORM研究

Karyopharm是一家专注于肿瘤学的制药公司，近日宣布，XPOVIO（Selinexor）治疗难治性多发性骨髓瘤患者的IIb期STORM研究结果已经发表于《新英格兰医学杂志》。

Blood：新型XPO1抑制剂对难治性非霍奇金淋巴瘤的疗效评估

核导出选择性抑制剂（SINE）化合物是一类新型的XPO1抑制剂。Selinexor在复发性或难治性NHL患者中的疗效是安全且有效的。